Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by Semliki Forest virus

被引:30
作者
Forsell, MNE
Li, YX
Sundbäck, M
Svehla, K
Liljeström, P
Mascola, JR
Wyatt, R
Hedestam, GBK
机构
[1] Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden
[2] Swedish Inst Infect Dis Control, Dept Vaccine Res, SE-17182 Solna, Sweden
[3] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1128/JVI.79.17.10902-10914.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The current lack of envelope glycoprotein immunogens that elicit broadly neutralizing antibody responses remains a major challenge for human immunodeficiency virus type 1 (HIV-1) vaccine development. However, the recent design and construction of stable soluble gp140 trimers have shown that some neutralization breadth can be achieved by using immunogens that better mimic the functional viral spike complex. The use of genetic delivery systems to drive the in vivo expression of such immunogens for the stimulation of neutralizing antibodies against HIV-1 may offer advantages by maintaining the quaternary structure of the trimeric envelope glycoproteins. Here, we describe the biochemical and immunogenic properties of soluble HIV-1 envelope glycoprotein trimers expressed by recombinant Semliki Forest virus (rSFV). The results presented here demonstrate that rSFV supports the expression of stable soluble gp140 trimers that retain recognition by conformationally sensitive antibodies. Further, we show that rSFV particle immunizations efficiently primed immune responses as measured after a single boost with purified trimeric gp140 protein, resulting in a Thl-biased antibody response. This differed from the Th2-biased antibody response obtained after repeated immunizations with purified gp140 protein trimers. Despite this difference, both regimens stimulated neutralizing antibody responses of similar potency. This suggests that rSFV may be a useful component of a viral vector prime-protein boost regimen aimed at stimulating both cell-mediated immune responses and neutralizing antibodies against HIV-1.
引用
收藏
页码:10902 / 10914
页数:13
相关论文
共 54 条
  • [1] The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
    Barnet, SW
    Lu, S
    Srivastava, I
    Cherpelis, S
    Gettie, A
    Blanchard, J
    Wang, S
    Mboudjeka, I
    Leung, L
    Lian, Y
    Fong, A
    Buckner, C
    Ly, A
    Hilt, S
    Ulmer, J
    Wild, CT
    Mascola, JR
    Stamatatos, L
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (12) : 5526 - 5540
  • [2] Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
    Berglund, P
    Fleeton, MN
    Smerdou, C
    Liljeström, P
    [J]. VACCINE, 1999, 17 (05) : 497 - 507
  • [3] PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160
    BERMAN, PW
    GREGORY, TJ
    RIDDLE, L
    NAKAMURA, GR
    CHAMPE, MA
    PORTER, JP
    WURM, FM
    HERSHBERG, RD
    COBB, EK
    EICHBERG, JW
    [J]. NATURE, 1990, 345 (6276) : 622 - 625
  • [4] A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
    Binley, JM
    Sanders, RW
    Clas, B
    Schuelke, N
    Master, A
    Guo, Y
    Kajumo, F
    Anselma, DJ
    Maddon, PJ
    Olson, WC
    Moore, JP
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (02) : 627 - 643
  • [5] Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity
    Brand, D
    Lemiale, F
    Thibault, G
    Verrier, B
    Lebigot, S
    Roingeard, P
    Buzelay, L
    Brunet, S
    Barin, F
    [J]. VIROLOGY, 2000, 271 (02) : 350 - 362
  • [6] HIV vaccine design and the neutralizing antibody problem
    Burton, DR
    Desrosiers, RC
    Doms, RW
    Koff, WC
    Kwong, PD
    Moore, JP
    Nabel, GJ
    Sodroski, J
    Wilson, IA
    Wyatt, RT
    [J]. NATURE IMMUNOLOGY, 2004, 5 (03) : 233 - 236
  • [7] Core structure of gp41 from the HIV envelope glycoprotein
    Chan, DC
    Fass, D
    Berger, JM
    Kim, PS
    [J]. CELL, 1997, 89 (02) : 263 - 273
  • [8] Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system
    Dong, M
    Zhang, PF
    Grieder, F
    Lee, J
    Krishnamurthy, G
    VanCott, T
    Broder, C
    Polonis, VR
    Yu, XF
    Shao, YM
    Faix, D
    Valente, P
    Quinnan, GV
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (05) : 3119 - 3130
  • [9] NATIVE OLIGOMERIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN ELICITS DIVERSE MONOCLONAL-ANTIBODY REACTIVITIES
    EARL, PL
    BRODER, CC
    LONG, D
    LEE, SA
    PETERSON, J
    CHAKRABARTI, S
    DOMS, RW
    MOSS, B
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (05) : 3015 - 3026
  • [10] Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
    Earl, PL
    Sugiura, W
    Montefiori, DC
    Broder, CC
    Lee, SA
    Wild, C
    Lifson, J
    Moss, B
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (02) : 645 - 653